Sulpin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulpin

Quick Facts

Property Description
Active ingredient Sulpiride
Form Tablet, Capsule, Solution for injection
Pharmacological class Antipsychotic agent (Substituted Benzamide)
Common use Management of psychotic and affective disorders
Origin Synthetic

What is Sulpin? Defining the Active Ingredient and Class

Sulpin is a prescription-only medication whose single active ingredient is Sulpiride. Sulpiride is a synthetic compound classified as an antipsychotic agent. This specific compound is also known by other trade names globally, confirming its widespread use and clinical recognition across different regulatory jurisdictions.

Sulpiride is chemically recognized as a substituted benzamide, which places it within the group of second-generation antipsychotics (atypical antipsychotics). Its key distinguishing characteristic is its selective profile. Pharmacological studies confirm that Sulpiride acts primarily as a selective Dopamine D2-receptor antagonist, which is the core mechanism underlying its effects on the central nervous system. This focused action is central to its therapeutic strategy, differentiating it from older agents by its targeted influence on the brain's signaling systems.

Understanding Sulpiride’s Purpose and Forms

The general purpose of Sulpiride is to help manage and relieve symptoms associated with psychotic and affective disorders by gently modulating brain chemistry. The drug's unique chemical structure allows it to target specific neural pathways, which is the basis for its utility in achieving a more settled and stable emotional state for patients.

The recognized effects of the compound include its use in addressing disturbances in thought, mood, and perception. This confirms that the medication is primarily designed to help stabilize and balance these key areas of mental function. For the practical function of treatment, Sulpiride is available in multiple dosage form(s), typically supplied as tablets or capsules for oral administration, and as a liquid injectable solution (parenteral route) when alternative or rapid administration is necessary. The availability of both solid oral and liquid forms represents a key characteristic of the formulation.

Regulatory References

  1. European Medicines Agency (EMA) Official Website

What side effects are possible with Sulpin?

Possible Side Effects and Safety Information

The safety profile of Sulpin (Sulpiride) is classified according to standard regulatory documentation, which groups adverse reactions by frequency and affected body system. The frequency categories used are Common, Uncommon, Rare, and Not Known, reflecting the likelihood of occurrence observed in clinical trials and post-marketing data.

Commonly documented side effects often involve the Nervous System (e.g., tremor, somnolence, insomnia) and Endocrine System, frequently including Hyperprolactinemia which can lead to related effects like galactorrhea. Weight gain is also a documented common reaction. Uncommon effects include Extrapyramidal disorders (such as dystonia and akathisia) and orthostatic hypotension.

Serious Adverse Reactions and Safety Constraints

Official labeling documents specific serious adverse reactions. These are typically Rare or of Not Known frequency, but require attention due to their clinical importance. Documented risks include Torsade de pointes and other Ventricular Arrhythmias, Neuroleptic Malignant Syndrome (NMS), and Venous Thromboembolism (VTE).

Regulatory safety constraints address high-risk scenarios. The medication is restricted from use in individuals with a known or suspected pheochromocytoma or prolactin-dependent tumors. Specific safety considerations are documented for older adults due to an increased risk of mortality when used for dementia-related psychosis, and for patients with pre-existing cardiac conditions that predispose to QTc prolongation.

Overdose and Emergency Response

Overdose Scope

The official regulatory documents define the Sulpin overdose profile by highlighting acute risks to the central nervous system and the cardiovascular system.

Property Documentation (Derived from Official Sources)
Documented overdose presentations Manifestations documented in prescribing information include altered consciousness, ranging from drowsiness and confusion to prolonged coma, alongside symptoms of agitation and lethargy. Movement disorders such as extrapyramidal symptoms (dystonic crises, trismus, torticollis) and cardiovascular signs like hypotension and sinus tachycardia are also documented.
Physiological systems affected Central Nervous System (CNS), Cardiovascular System, and Motor System.
Serious / Life-Threatening Outcomes The most serious outcomes are severe cardiac complications due to QTc prolongation, which potentiates the risk of life-threatening arrhythmias like Torsade de pointes and Ventricular Fibrillation, potentially leading to cardiac arrest. Neuroleptic Malignant Syndrome (NMS) is also a documented risk.
Population-specific overdose notes Patients with renal insufficiency may be at higher risk for drug accumulation, which could intensify overdose symptoms.
When immediate medical help is required Individuals who suspect an overdose must seek immediate medical attention. Urgent medical intervention is required if any signs of altered consciousness or arrhythmia are present.

Overdose Management

Official Overdose Statements:

  • No specific antidote is known for Sulpin overdose.
  • Management is strictly symptomatic and supportive.
  • Procedures described include gastric lavage and the administration of antiparkinsonian medication to manage severe extrapyramidal symptoms.
  • All patients require close monitoring for cardiac stability due to the risk of serious ventricular arrhythmias.

Therapeutic Uses of Sulpin

What Sulpin Treats: Main Uses and Benefits

Sulpiride is generally used to provide supportive symptomatic relief and supports patients during difficult episodes by easing distress and symptoms related to heightened physiological activity. The medication is commonly applied across clinical domains where additional symptomatic support is needed.

The therapeutic benefit primarily falls into three categories: managing complex psychotic and schizophrenic symptoms, supporting affective and mood disturbances, and offering relief for functional symptoms. This means it is relevant for easing symptoms associated with conditions characterized by periods of heightened symptoms such as schizophrenia, major depressive disorder (as an add-on therapy), dysthymia, and certain instances of debilitating vertigo and severe behavioral disorders.

The medication is commonly used to help with supporting emotional responsiveness and initiative, which may assist with patients coping more steadily with symptom fluctuations.

It is relevant for managing symptoms that interfere with daily comfort, particularly when they cluster into patterns requiring supportive symptom management.


Quick Fact: Supportive Management of Psychotic Symptoms

Category Symptom Domain
Primary Focus Psychotic Disorders (Acute/Chronic Schizophrenia)
Also relevant in Mood/Affective Disturbances
Used in Contexts of Functional Symptoms (Vertigo, Agitation)

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sulpin — Official Regulatory Information

The eligibility for using Sulpiride (Sulpin) is strictly defined by regulatory documents, outlining populations permitted for standard use, as well as those for whom the medicine is contraindicated or requires caution. Use is generally established for adults for its labeled indications.


Absolute Contraindications (Must Not Use)

Category Regulatory Status
Prolactin-Dependent Tumours Contraindicated
Phaeochromocytoma / Acute Porphyria Contraindicated
Levodopa or Antiparkinsonian Drugs Contraindicated (Concomitant Use)
Hypersensitivity to Sulpiride Contraindicated

Age and Condition Restrictions

Age: The medicine is not recommended for children under 14 years due to insufficient clinical experience. Older adults require particular caution due to increased susceptibility to effects like hypotension, and dose reduction is necessary if renal function is impaired.

Physiological Status: Use is not recommended during pregnancy or lactation (breastfeeding).

Comorbidities: Caution is required for patients with a history of Epilepsy or existing Parkinson's Disease. Caution is also necessary for patients with risk factors for QT prolongation or Venous Thromboembolism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions QT-prolonging medicines, Bradycardia-inducing medicines, CNS Depressants, Antihypertensive Agents, Antacids, and Sucralfate.
Specific interacting medicines (if explicitly listed) Levodopa, Alcohol, Lithium, Metoclopramide, Beta-blockers, Digitalis, Clonidine, and certain Antihypertensive agents.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic antagonism (Levodopa), Pharmacodynamic potentiation (CNS depressants, QT risk), and Reduced Absorption (Antacids/Sucralfate).
Timing-based interaction rules (if applicable) Must be administered two hours before Antacids or Sucralfate to maintain adequate systemic exposure.
Population-specific interaction notes (if applicable) Increased risk of hypertensive crisis noted in elderly hypertensive patients co-administered with certain agents.
Interaction-related restrictions Contraindicated with Levodopa; Avoidance of alcohol is mandatory.

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation
Interaction severity classification Contraindicated Combination, Not Recommended Combination (e.g., QT-prolonging agents), and Avoidance Mandatory (Alcohol).
Regulatory basis Summary of Product Characteristics (SmPC) and equivalent health authority documentation.
Interaction-context constraints Mandatory timing separation from absorption-reducing agents is required. Exposure to alcohol must be eliminated due to sedative potentiation.

Official Interaction Statements

Official regulatory documents classify use with Levodopa as a contraindicated combination due to reciprocal pharmacodynamic antagonism. Co-administration with alcohol must be strictly avoided as it formally potentiates the medication’s sedative effects. Use with drugs that prolong the QT interval or induce bradycardia is officially not recommended due to the additive risk of serious ventricular arrhythmias. Substances that reduce absorption, specifically Antacids and Sucralfate, necessitate a formal timing separation rule, requiring Sulpiride to be taken two hours prior to these products. Furthermore, the profile confirms a low metabolic interaction risk as the substance does not inhibit or stimulate major CYP enzymes.

Connection to the overall interaction profile

Regulatory documents define the product’s interaction structure by highlighting critical pharmacodynamic risks associated with cardiac effects and CNS depression, resulting in absolute prohibitions and non-recommendations. The profile also features constraints related to reduced absorption by specific substances, which mandates a precautionary timing separation rule documented in the regulatory labeling.

Mechanism of Action

Sulpin is an atypical psychotropic compound that acts primarily within the central nervous system by modulating key monoamine pathways. Its pharmacodynamic mechanism is complex, involving dose-dependent interactions with the dopamine receptor system.


Dopamine Receptor Antagonism

Sulpin acts as an antagonist at the postsynaptic Dopamine D2 and D3 receptors. This direct interaction with the receptor binding site modulates signal transmission within specific dopaminergic pathways, influencing neuronal circuit activity. The subsequent shift in activity equilibrium contributes to defined alterations in physiological state.


Dose-Dependent Pathway Modulation

At lower concentrations, Sulpin exhibits a unique action by preferentially blocking the presynaptic inhibitory D2 autoreceptors. Antagonism of these autoreceptors initiates a signaling cascade that increases the synthesis and release of dopamine into the synaptic cleft, influencing subsequent signal transduction based on the administered concentration.


Selective Neurotransmitter Engagement

The compound is characterized by its relative selectivity, displaying negligible affinity for numerous other neurotransmitter receptors, including those for histamine, norepinephrine, and acetylcholine. This selective binding profile dictates the scope of its pathway activity, focusing the modulation on specific mediator systems.

Dosage and Administration Information

How Sulpin is Used: General Administration Guidelines

The usage of Sulpin (Sulpiride) follows established parameters for its administration and dosage. This ensures adherence to standardized clinical practice.


Administration Routes and Dosing Structure

Sulpiride is administered via the oral route (using tablets, capsules, or solution) or through an intramuscular injection when rapid administration is clinically necessary. The standard adult dosing schedule requires the total daily amount to be divided, typically resulting in two separate administrations daily.

Dosing ranges are wide and depend on the required treatment approach. While a common starting dose is between 400 mg and 800 mg daily, the maximum dose for acute situations can reach 2400 mg daily. The final dose is typically adjusted according to the patient's individual response.


Administration Conditions and Population Adjustments

Practical guidelines detail how the medicine should be taken. Oral tablets should be swallowed whole with an appropriate amount of water. Furthermore, to prevent reduced absorption, Sulpiride is taken at least two hours before the administration of antacids or sucralfate.

Specific adjustments are utilized for certain patient populations. For individuals with impaired kidney function, the dose is typically reduced or the time interval between doses increased based on creatinine clearance. The medicine is generally not recommended for use in children under 14 years due to a lack of sufficient clinical experience and guidance within established clinical labels.

Recent Clinical Evidence

Research evidence / Overview of studies for Sulpin


Evidence for Use in Schizophrenia and Psychotic Disorders

Research into Sulpiride was studied for schizophrenia and related psychotic disorders, which has been a primary focus since its introduction. This work involved various study types, predominantly short-term Randomized Controlled Trials (RCTs) and systematic reviews, which were applied in studies monitoring symptom patterns over defined time intervals. These studies were relevant in trials assessing short-term or episodic symptom patterns, primarily focused on adult populations.

Studies describe how symptoms evolved in the observed populations during the defined time intervals of the research. Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations over the short term. Research explored the assessment of negative symptom outcomes in trials, but the findings were mixed, and the evidence base is less consistent in this specific area. Evidence quality varies across studies, and some older trials are described as having modest sample sizes and other methodological limitations.


Evidence for Adjunctive Use in Major Depressive Disorder

Sulpiride was also evaluated in research contexts involving fluctuating or unstable symptoms as an add-on therapy for Major Depressive Disorder (MDD). The research primarily involves smaller Randomized Controlled Trials and open-label studies where it was combined with conventional antidepressant medications. The studies monitored whether the addition of Sulpiride related to a measured difference in the time to reach defined outcome thresholds.

Studies described how symptoms evolved in the observed populations when Sulpiride was used alongside another medicine, with findings describing a measured change in mood scale scores in some patients during the study period. However, this research provides insight into short-term changes only, and the evidence quality varies across studies.


What Is Still Uncertain About Sulpin's Evidence Base

Scientific literature points to several areas where the research evidence is limited or certainty remains low. The methodological quality of some older clinical studies is often cited as a limitation. Research highlights areas where comparative evidence is lacking—specifically, large-scale, head-to-head trials against newer treatments for long-term outcomes. Furthermore, the evidence base for long-term functional outcomes across all indications is limited, meaning studies provide context but not individual predictions about symptom stability or sustained recovery over many years.

Frequently Asked Questions (FAQ)

Common questions about Sulpin (FAQ)

Q: Is Sulpin a type of antidepressant?

Official documents classify Sulpin as an atypical psychotropic or antipsychotic medicine, meaning it primarily affects chemical messengers in the brain. While it has been studied and may be used as an add-on therapy for some patients with Major Depressive Disorder, its main classification is not an antidepressant.

Q: Is it normal to feel drowsy when starting Sulpin?

Drowsiness, often referred to as somnolence in regulatory documents, is one of the reactions that has been commonly reported in patients using this medicine. Official information notes that caution is advised regarding activities like driving or operating machinery when starting treatment.

Q: Is Sulpin safe to use long-term?

Sulpin has official indications that cover both acute and chronic conditions, suggesting it is prescribed for extended periods. However, regulatory documents mention that research focused on long-term functional outcomes is often limited, and studies monitor effects primarily over the short term.

Q: How long does Sulpin stay in the body?

Pharmacokinetic studies, which describe how the body processes the medicine, indicate that the apparent elimination half-life of Sulpin is typically 6 to 8 hours. This measurement represents the time required for half the medicine to be removed from the body.

Q: Is it safe to stop taking Sulpin suddenly?

Regulatory guidance typically recommends that discontinuation of treatment be carried out gradually, rather than suddenly. Stopping treatment rapidly may be associated with symptoms like nausea, vomiting, or movement disorders.

Q: How does the time of day I take Sulpin impact its effects?

Regulatory guidance specifies that the total daily dose should be divided and typically given in two separate administrations daily. Beyond this, official information does not generally specify required morning or evening timing, as administration may depend on the condition being treated.

Q: Does official labeling for Sulpin mention its use in children or adolescents?

Official labeling generally restricts the use of Sulpin in younger age groups. It is not recommended for use in children younger than 14 years of age due to limited clinical data and established guidance for this population.

Q: How quickly should I expect Sulpin to start working?

Official product information does not specify an exact onset time for effects. As is common for many medicines in this category, it may take several days or weeks before a noticeable change in symptoms is typically observed in studies and patient reports.

Q: Can Sulpin be used for anxiety or just depression?

Official documents for Sulpin in some regions specify its use for the short-term treatment of anxiety symptoms in adults, particularly when other treatments have not been successful. It is also approved for conditions like schizophrenia and for Major Depressive Disorder in an adjunctive (add-on) capacity.

Q: Is hair loss a reported side effect of Sulpin?

Hair loss is not typically listed among the common, uncommon, or rare side effects in the official regulatory documents. The documented adverse reaction lists generally focus on more frequently or seriously reported events.

Q: Are there any food restrictions while taking Sulpin?

Official labeling does not typically list specific food restrictions. The only formal timing restriction involves medicines like antacids or sucralfate; Sulpin must be taken two hours before these products to prevent reduced absorption.

Q: Can I take Sulpin if I'm already taking a blood pressure medication?

Official documents describe that co-administration with antihypertensive agents (blood pressure medication) may lead to an additive hypotensive effect, meaning a potentially greater reduction in blood pressure. Official documents describe that co-administration requires assessment due to the risk of an additive hypotensive effect.

Q: What happens if I forget to take a dose of Sulpin?

Regulatory patient information generally contains specific instructions for a missed dose, often stating that the missed dose should be taken if remembered soon after the scheduled time, or skipped if it is near the next scheduled dose. Double dosing is typically advised against.

Q: Does Sulpin affect sleep patterns?

Yes, official safety data indicates that Sulpin can affect sleep. The profile reports insomnia (difficulty falling or staying asleep) and somnolence (drowsiness or sleepiness) as commonly documented side effects.

Q: Is Sulpin considered a controlled substance?

Based on official governmental classifications of medicines, Sulpin is not typically scheduled as a controlled substance in major jurisdictions. It is not generally associated with potential for abuse or dependence.

Q: Do studies show that Sulpin is effective?

Regulatory documents state that in controlled clinical studies, Sulpin has been shown to be effective compared to placebo in the management of its indicated conditions. The evidence supports its use for the conditions outlined in its official label.

Q: What is the risk of dependence or addiction with Sulpin?

Official regulatory information does not commonly cite Sulpin as having a risk of dependence or addiction. However, specific guidance is given regarding a potential discontinuation syndrome that can occur after abrupt cessation (sudden stopping).

Q: Can Sulpin affect driving ability?

Yes, official guidance advises that Sulpin may cause sedation or dizziness. Patients are typically warned that the medicine may impair their ability to drive vehicles or operate machinery, and caution is officially recommended.

Q: Is it possible to take Sulpin while pregnant?

Official guidance generally recommends avoiding Sulpin during pregnancy, particularly during the first trimester. Use during pregnancy is described as being reserved for situations where the potential benefit is judged to outweigh the known or potential risks to the fetus.

Q: Will Sulpin interfere with birth control pills?

Official documentation states that Sulpin does not significantly affect or inhibit the major enzymes (CYP enzymes) that break down medicines. This characteristic is typically associated with a low risk of pharmacokinetic interaction with hormonal contraceptives.

Q: Does Sulpin affect blood sugar levels?

Yes, regulatory documents report that changes in blood glucose levels have been documented as possible side effects. This includes reports of both hyperglycemia (high blood sugar) and, less frequently, hypoglycemia (low blood sugar).

Q: Is it known if Sulpin is safe for breastfeeding mothers?

Regulatory guidance often advises against breastfeeding while using Sulpin. It is known to pass into breast milk, and official documents note that a risk to the nursing infant cannot be formally ruled out.

Q: Can Sulpin cause unusual dreams or nightmares?

While the official labeling documents common sleep-related effects like insomnia, nightmares or abnormal dreams are not usually listed among the common side effects in official documents. The effects on sleep are typically limited to somnolence and insomnia.

Q: Can Sulpin cause changes in mood that feel unusual?

Yes, the official safety profile documents adverse events such as agitation, confusion, or, in rare cases, manic states as possible reactions. These are classified under psychiatric disorders in the official labeling.

Q: Are there specific tests needed before starting Sulpin?

Official documentation generally mandates a pre-treatment check. This includes ruling out certain tumors and assessing risk factors for QTc prolongation (an effect on heart rhythm) through means such as an ECG (electrocardiogram) in patients who are considered to be at risk.

Q: Can Sulpin cause digestive issues like nausea or diarrhea?

Official adverse event lists document gastrointestinal issues. While constipation is listed as a common side effect, events such as nausea and vomiting have also been reported as documented reactions in the official safety profile.

Q: Does Sulpin interact with common cold or flu medications?

Official documents warn against combining Sulpin with other medicines that prolong the QT interval (a heart rhythm measure) or cause CNS depression (sedation). Due to these potential risks, the use of Sulpin with these medications is generally subject to review.

Q: Are there any specific lifestyle changes that are mentioned in official guidance for Sulpin users?

Official guidance strictly mandates the avoidance of alcohol while using this medicine. Furthermore, official information includes warnings about the risk of dizziness or drowsiness, advising caution regarding activities like driving or operating machinery.

How should Sulpin be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates strict conditions for the storage and disposal of Sulpiride (Sulpin) to ensure product stability and safety.

Requirement Area Official Labeled Condition
Temperature Limit Do not store above 25 C
Environmental Protection Store in a dry place and protect from light
Shelf-Life 3 years (when stored correctly and unopened)
Child Safety Keep out of the sight and reach of children
Disposal Do not dispose of via wastewater or routine household trash

These mandated conditions ensure the medicine maintains its quality throughout its defined 3-year shelf-life. Expired or unused Sulpiride must not be discarded into the environment, and its final disposal requires adherence to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulpin found in:

A-Z Index: